43 THORNDIKE STREET, CAMBRIDGE, MA
Manufacturing and Supply Agreement with Bachem and Polypeptide Signed
Amylyx Pharmaceuticals Enters Underwriting Agreement for 14.09M Shares
Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
Investor Presentation
Reports Second Quarter 2026 Financial Results
Election of Class II Directors at Amylyx Pharmaceuticals Annual Meeting
Reports First Quarter 2026 Financial Results
Annual Report to Security Holders
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities